EXEL
Price
$21.53
Change
+$0.82 (+3.96%)
Updated
Feb 23, 6:59 PM EST
72 days until earnings call
INCY
Price
$60.59
Change
-$0.32 (-0.53%)
Updated
Feb 23, 6:59 PM EST
65 days until earnings call
Ad is loading...

EXEL vs INCY ᐉ Comparison: Which is Better to Invest?

Header iconEXEL vs INCY Comparison
Open Charts EXEL vs INCYBanner chart's image
Exelixis
Price$21.53
Change+$0.82 (+3.96%)
Volume$1.65M
CapitalizationN/A
Incyte
Price$60.59
Change-$0.32 (-0.53%)
Volume$726.56K
CapitalizationN/A
View a ticker or compare two or three
EXEL vs INCY Comparison Chart

Loading...

EXELDaily Signal changed days agoGain/Loss if shorted
 
Show more...
INCYDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
EXEL vs. INCY commentary
Feb 25, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EXEL is a Hold and INCY is a StrongSell.

COMPARISON
Comparison
Feb 25, 2024
Stock price -- (EXEL: $21.53 vs. INCY: $60.59)
Brand notoriety: EXEL and INCY are both notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: EXEL: 129% vs. INCY: 89%
Market capitalization -- EXEL: $6.53B vs. INCY: $13.6B
EXEL [@Biotechnology] is valued at $6.53B. INCY’s [@Biotechnology] market capitalization is $13.6B. The market cap for tickers in the [@Biotechnology] industry ranges from $550.21B to $0. The average market capitalization across the [@Biotechnology] industry is $2.58B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EXEL’s FA Score shows that 0 FA rating(s) are green whileINCY’s FA Score has 0 green FA rating(s).

  • EXEL’s FA Score: 0 green, 5 red.
  • INCY’s FA Score: 0 green, 5 red.
According to our system of comparison, EXEL is a better buy in the long-term than INCY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EXEL’s TA Score shows that 5 TA indicator(s) are bullish while INCY’s TA Score has 4 bullish TA indicator(s).

  • EXEL’s TA Score: 5 bullish, 5 bearish.
  • INCY’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, EXEL is a better buy in the short-term than INCY.

Price Growth

EXEL (@Biotechnology) experienced а +5.13% price change this week, while INCY (@Biotechnology) price change was +4.54% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.03%. For the same industry, the average monthly price growth was +18.51%, and the average quarterly price growth was +38.88%.

Reported Earning Dates

EXEL is expected to report earnings on May 07, 2024.

INCY is expected to report earnings on Apr 30, 2024.

Industries' Descriptions

@Biotechnology (+2.03% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for EXEL with price predictions.
OPEN
A.I.dvisor published
a Summary for INCY with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
INCY($13.6B) has a higher market cap than EXEL($6.53B). EXEL has higher P/E ratio than INCY: EXEL (33.12) vs INCY (22.86). INCY YTD gains are higher at: -3.504 vs. EXEL (-10.254). INCY has higher annual earnings (EBITDA): 919M vs. EXEL (197M). INCY has more cash in the bank: 3.66B vs. EXEL (995M). INCY has less debt than EXEL: INCY (38.3M) vs EXEL (190M). INCY has higher revenues than EXEL: INCY (3.7B) vs EXEL (1.83B).
EXELINCYEXEL / INCY
Capitalization6.53B13.6B48%
EBITDA197M919M21%
Gain YTD-10.254-3.504293%
P/E Ratio33.1222.86145%
Revenue1.83B3.7B50%
Total Cash995M3.66B27%
Total Debt190M38.3M496%
FUNDAMENTALS RATINGS
EXEL vs INCY: Fundamental Ratings
EXEL
INCY
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
74
Overvalued
67
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
7563
PRICE GROWTH RATING
1..100
5456
P/E GROWTH RATING
1..100
4892
SEASONALITY SCORE
1..100
49n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

INCY's Valuation (67) in the Biotechnology industry is in the same range as EXEL (74). This means that INCY’s stock grew similarly to EXEL’s over the last 12 months.

INCY's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as EXEL (100). This means that INCY’s stock grew similarly to EXEL’s over the last 12 months.

INCY's SMR Rating (63) in the Biotechnology industry is in the same range as EXEL (75). This means that INCY’s stock grew similarly to EXEL’s over the last 12 months.

EXEL's Price Growth Rating (54) in the Biotechnology industry is in the same range as INCY (56). This means that EXEL’s stock grew similarly to INCY’s over the last 12 months.

EXEL's P/E Growth Rating (48) in the Biotechnology industry is somewhat better than the same rating for INCY (92). This means that EXEL’s stock grew somewhat faster than INCY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EXELINCY
RSI
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
62%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
61%
Bearish Trend 2 days ago
62%
Momentum
ODDS (%)
Bullish Trend 2 days ago
66%
Bullish Trend 2 days ago
58%
MACD
ODDS (%)
Bullish Trend 2 days ago
66%
Bullish Trend 2 days ago
60%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
67%
Bullish Trend 2 days ago
60%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
65%
Bearish Trend 2 days ago
65%
Advances
ODDS (%)
Bullish Trend 3 days ago
64%
Bullish Trend 3 days ago
59%
Declines
ODDS (%)
Bearish Trend 20 days ago
68%
Bearish Trend 20 days ago
64%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
64%
Aroon
ODDS (%)
Bearish Trend 2 days ago
60%
Bearish Trend 2 days ago
67%
View a ticker or compare two or three
Ad is loading...
EXELDaily Signal changed days agoGain/Loss if shorted
 
Show more...
INCYDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
LDP19.470.18
+0.93%
Cohen & Steers Limited
PAVE37.090.26
+0.71%
Global X US Infrastructure Dev ETF
TMDV46.570.06
+0.14%
ProShares Russell US Dividend Grwr ETF
RSPC28.93-0.11
-0.37%
Invesco Exchange-Traded Fund Trust Invesco S&P 500 Equal Weight Communication Services ETF
ERTH41.31-0.46
-1.09%
Invesco MSCI Sustainable Future ETF

EXEL and

Correlation & Price change

A.I.dvisor indicates that over the last year, EXEL has been loosely correlated with SRPT. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if EXEL jumps, then SRPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EXEL
1D Price
Change %
EXEL100%
+3.96%
SRPT - EXEL
36%
Loosely correlated
+1.30%
INCY - EXEL
35%
Loosely correlated
-0.53%
RVMD - EXEL
34%
Loosely correlated
+2.38%
ALNY - EXEL
34%
Loosely correlated
-3.17%
ADMA - EXEL
33%
Poorly correlated
N/A
More

INCY and

Correlation & Price change

A.I.dvisor indicates that over the last year, INCY has been loosely correlated with EXEL. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if INCY jumps, then EXEL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INCY
1D Price
Change %
INCY100%
-0.53%
EXEL - INCY
45%
Loosely correlated
+3.96%
JAZZ - INCY
40%
Loosely correlated
+2.98%
AXON - INCY
39%
Loosely correlated
-0.34%
BMRN - INCY
38%
Loosely correlated
+1.41%
CCCC - INCY
36%
Loosely correlated
+2.16%
More